Summary
- Current Price
- As of today, BBIO price is $84.48, up +2.03% on
- Current Price All-Time High
- BBIO price is currently -9.56% below its historical high of $93.42 set on
- Market Cap
- BBIO current market cap is $17B, up +88.37% over the past 365 days
- Revenue
- BBIO current annual revenue is $502.08M, up +126.26% year-over-year
- Next Earnings
- The next earnings release for BBIO is on
Profile
| Metric | Value |
|---|---|
| Full Name | BridgeBio Pharma, Inc. |
| Ticker | NASDAQ: BBIO |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | bridgebio.com |
| Employees | 725 |
Key Metrics
| Metric | Value | Date |
|---|---|---|
| Price | $84.48 | |
| Price, 1D Change | +2.03% | |
| Market Cap | $17B | |
| - | ||
| PE Ratio | - | |
| Beta | 1.17 | |
| Revenue | $502.08M | |
| Revenue, 1Y Change | +126.26% | |
| EPS | -$3.79 | |
| EPS, 1Y Change | -31.46% |
Chart
SUGGESTED SERIES
Events
| Metric | Value | Date |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Value | Date |
|---|---|---|
| EPS | -$3.79 | |
| EPS Estimate | -$2.19 | N/A |
| EPS Est. Change | +42.17% | N/A |
| Revenue | $502.08M | |
| Revenue Estimate | $960.73M | N/A |
| Revenue Est. Change | +91.35% | N/A |
| Current Price | $84.48 | |
| Price Target | $102.00 | - |
| Price Tgt. Change | +20.74% | - |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$2.39 | -$2.88 | -20.37% | |
| -$3.19 | -$3.79 | -18.65% | |
| -$2.19 | N/A | +42.17% | |
| $0.58 | N/A | +115.33% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $281.76M | $221.90M | -21.24% | |
| $497.54M | $502.08M | +0.91% | |
| $960.73M | N/A | +91.35% | |
| $1.61B | N/A | +221.07% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Value | Date |
|---|---|---|
| Price, 1Y | +83.85% | |
| Price, 3Y | +172.87% | |
| Market Cap, 1Y | +88.37% | |
| Market Cap, 3Y | +231.09% | |
| Revenue, 1Y | +126.26% | |
| Revenue, 3Y | +546.61% | |
| EPS, 1Y | -31.46% | |
| EPS, 3Y | -16.00% |
🔒 Log In To Unlock Full Data
Technicals
| Metric | Value | Date |
|---|---|---|
| Current Price | $84.48 | |
| SMA 200 | $72.04 | |
| SMA 50 | $75.51 | |
| EMA 200 | $69.35 | |
| EMA 50 | $77.77 | |
| MACD | $1.74 | |
| Beta | 1.17 | |
| ATR | $2.89 | |
| 14-Day RSI | 61.10 | |
| 10-Day Volatility | 28.77% |
Dividends
| Metric | Value | Date |
|---|---|---|
| - | N/A | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| $0.00 | ||
| 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Value | Date |
|---|---|---|
| Revenue | $502.08M | |
| EPS | -$3.79 | |
| Gross Profit | $478.38M | |
| Gross Margin | 95.28% | |
| Operating Income | -$502.06M | |
| Operating Margin | -100.00% | |
| Net Income | -$732.94M | |
| Net Margin | -145.98% | |
| EBITDA | -$496.63M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Value | Date |
|---|---|---|
| Debt To Equity | -1.31 | |
| 2.77 | ||
| 2.68 | ||
| - | ||
| 2 | ||
| -3.00 |
Valuations
| Metric | Value | Date |
|---|---|---|
| PE Ratio | - | |
| 28.53 | ||
| -7.26 | ||
| -38.07 | ||
| - | N/A |
Balance Sheet
| Metric | Value | Date |
|---|---|---|
| Book Value | -$2.09B | |
| $588.03M | ||
| $936.03M | ||
| $797.75M | ||
| $3.01B | ||
| $287.97M | ||
| Total Debt | $2.73B | |
| $17.41M | ||
| $36.23M |
Expenses
| Metric | Value | Date |
|---|---|---|
| $1.23B | ||
| $980.44M | ||
| $23.70M | ||
| $0.00 | ||
| $5.43M | ||
| $0.00 | ||
| $435.00K |
Cash Flow
| Metric | Value | Date |
|---|---|---|
| -$445.91M | ||
| -$22.34M | ||
| $357.14M | ||
| Capex | $9.59M | |
| -$455.50M |
Recent analyst updates
| Metric | Value | Date |
|---|---|---|
| Citigroup | → | |
| HC Wainwright & Co. | → | |
| Mizuho | → | |
| Canaccord Genuity | ||
| Morgan Stanley | → | |
| HC Wainwright & Co. | → | |
| Raymond James | → | |
| Citigroup | ||
| HC Wainwright & Co. | → | |
| Evercore ISI Group | → |
Analyst sentiment
Institutional ownership
Screeners with BBIO
FAQ
- What is the ticker symbol for BridgeBio Pharma, Inc.?
- The ticker symbol for BridgeBio Pharma, Inc. is NASDAQ:BBIO
- Does BridgeBio Pharma, Inc. pay dividends?
- No, BridgeBio Pharma, Inc. does not pay dividends
- What sector is BridgeBio Pharma, Inc. in?
- BridgeBio Pharma, Inc. is in the Healthcare sector
- What industry is BridgeBio Pharma, Inc. in?
- BridgeBio Pharma, Inc. is in the Biotechnology industry
- What country is BridgeBio Pharma, Inc. based in?
- BridgeBio Pharma, Inc. is headquartered in United States
- When did BridgeBio Pharma, Inc. go public?
- BridgeBio Pharma, Inc. initial public offering (IPO) was on June 27, 2019
- Is BridgeBio Pharma, Inc. in the S&P 500?
- No, BridgeBio Pharma, Inc. is not included in the S&P 500 index
- Is BridgeBio Pharma, Inc. in the NASDAQ 100?
- No, BridgeBio Pharma, Inc. is not included in the NASDAQ 100 index
- Is BridgeBio Pharma, Inc. in the Dow Jones?
- No, BridgeBio Pharma, Inc. is not included in the Dow Jones index
- When was BridgeBio Pharma, Inc. last earnings report?
- BridgeBio Pharma, Inc.'s most recent earnings report was on May 7, 2026
- When does BridgeBio Pharma, Inc. report earnings?
- The next expected earnings date for BridgeBio Pharma, Inc. is August 10, 2026
Data Sources & References
- BBIO Official Website bridgebio.com
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1743881/000174388126000009/0001743881-26-000009-index.htm
- BBIO Profile on Yahoo Finance finance.yahoo.com/quote/BBIO
- BBIO Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/bbio